Blue Jet Healthcare Announces ₹2,300 Crore Pharmaceutical Manufacturing Facility in Andhra Pradesh
核心洞察
Blue Jet Healthcare (搜索) will invest ₹2,300 crore to establish a greenfield pharmaceutical manufacturing facility at Rambilli Industrial Park (搜索) in Anakapalli district, Andhra Pradesh, spanning 102 acres.
The facility will produce contrast media intermediates (搜索), high-intensity sweeteners (搜索), and multipurpose chemistry products, with operations expected to begin by FY2028-29.
The project will create 1,750 direct jobs and 250 indirect jobs while incorporating zero liquid discharge technology designed to reduce energy consumption by 70% and recover 90-95% of wastewater.
Blue Jet Healthcare (搜索) Ltd will break ground on a ₹2,300-crore greenfield pharmaceutical manufacturing facility at Rambilli Industrial Park (搜索) in Anakapalli district, Andhra Pradesh, marking a significant expansion of India's specialty pharmaceutical and Contract Development and Manufacturing Organisation (CDMO) capabilities.
The 102-acre facility will produce contrast media intermediates (搜索), high-intensity sweeteners (搜索), and multipurpose chemistry products. Developed in phases, the plant is expected to become operational by FY2028-29, according to official sources.
Strategic Investment in Specialty Chemistry
Founded in 1968 as Jet Chemicals Pvt Ltd (搜索), Blue Jet Healthcare (搜索) has evolved into an integrated CDMO, supplying advanced pharmaceutical intermediates (搜索) and active pharmaceutical ingredients (APIs) to markets in India, Europe, and the United States. The company has established itself as a leading player in contrast media intermediates (搜索) and was an early pioneer of saccharin production in India.
Over decades, Blue Jet has built deep expertise in process chemistry, manufacturing scale-up, and global regulatory-compliant production, positioning itself as a strategic supplier to multinational pharmaceutical companies.
Employment and Economic Impact
The Rambilli project is projected to generate 1,750 direct jobs and 250 indirect jobs, significantly strengthening the industrial profile of the Visakhapatnam economic region. The investment is expected to deepen India's domestic manufacturing base in high-value specialty intermediates at a time when global pharmaceutical companies are increasingly diversifying supply chains beyond single geographies.
Environmental Sustainability Features
The new plant will feature zero liquid discharge (ZLD) technology and an advanced effluent treatment plant with marine discharge connectivity. According to the company profile, this system is designed to enable a 70% reduction in energy consumption while recovering 90-95% of wastewater—a critical factor as global pharmaceutical supply chains tighten environmental, social, and governance (ESG) and compliance benchmarks.
Leadership and Strategic Vision
The company is led by Executive Chairman Akshay Bansarilal Arora, who has been associated with the business for over four decades and has served on the Board since 1983. With academic training in chemistry and extensive experience in specialty chemicals and pharmaceuticals, he has been instrumental in transforming Blue Jet into a global supplier of contrast media intermediates (搜索) and niche pharmaceutical products.
Managing Director Shiven Akshay Arora, who joined the Board in 2015, oversees expansion initiatives and global strategy, with a focus on modernization, innovation, and greenfield developments.
Regional Development and Industry Positioning
For Andhra Pradesh, the groundbreaking signals further momentum in its cluster-based industrial push, particularly in pharmaceuticals and bulk drugs. The Rambilli Industrial Park (搜索) is being positioned as a hub for high-value chemical and pharmaceutical manufacturing along India's eastern coast.
The expansion reinforces Blue Jet's strategy to scale its global CDMO footprint and supports India's ambition to move up the pharmaceutical value chain from generics to complex intermediates and specialty chemistry. The investment represents a long-term commitment to India's specialty chemistry and pharmaceutical value chain, supporting the country's push toward global supply-chain diversification.